CD8A and non-small cell lung carcinoma: Patients with NSCLC receiving immune checkpoint blockade (ICB, n = 114) or not receiving ICB (no-ICB, n = 372) had better OS with high CD8+, PD-1+, or CD8+PD-1+ cells (all P < .001, Data Supplement, Fig S5).